| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The peptide binds to the MHC class I molecule H‑2Dᵇ on the surface of antigen‑presenting cells. This complex is then recognized by CD8+ T‑cell receptors on cytotoxic T lymphocytes, leading to T‑cell activation and lysis of the presenting cells. In transplantation settings, this recognition underlies the rejection of male grafts by female recipients.
|
|---|---|
| ln Vitro |
In vitro cytotoxicity assays using female mouse splenocytes as effector cells and male mouse target cells (or peptide‑pulsed female target cells) demonstrate that the Uty HY peptide (1‑10 ug/mL) specifically sensitizes H‑2ᵇ‑expressing target cells to lysis by T cells from female mice immunized with male cells. The lytic activity is dose‑dependent and can be measured by ⁵¹Cr release or flow cytometry‑based killing assays.
|
| ln Vivo |
In female mice of the H‑2ᵇ haplotype (e.g., C57BL/6), a single subcutaneous or intraperitoneal injection of Uty HY peptide (50‑200 ug) emulsified in complete Freund's adjuvant (CFA) induces a strong CD8+ T‑cell response against male cells. When these immunized female mice are subsequently transplanted with male skin grafts, the grafts are rejected in an accelerated, T‑cell‑dependent manner (median survival time <20 days compared to >50 days in non‑immunized females).
|
| Enzyme Assay |
A direct binding assay between the peptide and H‑2Dᵇ molecules is performed using surface plasmon resonance (SPR) or a competition‑based refolding assay. For the refolding assay, recombinant H‑2Dᵇ heavy chain and beta2‑microglobulin are denatured and then diluted into refolding buffer containing the Uty HY peptide (10‑100 uM). The refolded MHC‑peptide complex is detected by a conformation‑specific antibody (e.g., 28‑14‑8S). Alternatively, RMA‑S cells (a transporter‑associated with antigen processing‑deficient cell line) can be pulsed with the peptide and tested for surface H‑2Dᵇ‑peptide complexes by flow cytometry.
|
| Cell Assay |
RMA‑S cells (H‑2ᵇ) are incubated with the Uty HY peptide (0.01‑100 uM) overnight at 26degC to allow exogenous peptide binding to empty MHC I molecules. The cells are then shifted to 37degC for 2 hours to stabilize the complexes. Surface expression of H‑2Dᵇ‑peptide complexes is detected by staining with an anti‑H‑2Dᵇ antibody (e.g., clone 34‑2‑12) and analyzed by flow cytometry. For T‑cell activation assays, female splenocytes are cultured with peptide‑pulsed and irradiated male splenocytes for 5 days, then the cytotoxic activity is tested.
|
| Animal Protocol |
C57BL/6 female mice (6‑8 weeks old) are immunized subcutaneously at the base of the tail with 100 ug of Uty HY peptide emulsified in 100 uL of CFA. After 7‑10 days, the mice are challenged by subcutaneous transplantation of a full‑thickness skin graft from a male C57BL/6 donor. Graft survival is monitored daily by visual inspection and palpation; rejection is defined as >90% graft necrosis. Alternatively, splenocytes from immunized mice can be harvested and tested for ex vivo cytotoxicity.
|
| ADME/Pharmacokinetics |
The peptide itself has a very short half‑life in plasma (<10 minutes) due to rapid proteolysis. The TFA salt does not change this. The 9‑mer peptide is small enough to be filtered by the kidney and degraded in the renal tubules. To induce T‑cell responses, the peptide must be formulated in an adjuvant (e.g., CFA) that prolongs its presence at the injection site and activates innate immunity.
|
| Toxicity/Toxicokinetics |
The Uty HY peptide is non‑toxic at the doses used in mice (<200 ug). The CFA emulsion can cause local injection site reactions (granulomas) and, rarely, systemic inflammatory responses. The TFA counterion does not contribute to toxicity at these concentrations. No genotoxicity or organ toxicity has been reported.
|
| References |
[1]. Greenfield A, et al. An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat Genet. 1996;14(4):474-478.
|
| Additional Infomation |
The Uty HY peptide is a well‑defined model antigen for studying CD8+ T‑cell responses, transplantation immunology, and immune tolerance. It is one of the few known H‑Y epitopes in the H‑2ᵇ haplotype. The peptide is widely used to investigate mechanisms of graft rejection, to test the efficacy of immunosuppressive drugs, and to study T‑cell receptor recognition. It is not a therapeutic agent and is for research use only.
|
| Molecular Formula |
C55H78F3N15O15S2
|
|---|---|
| Related CAS # |
Uty HY Peptide (246-254);261172-28-5
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~12.5 mg/mL (~9.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (76.31 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
